Advances in pharmacotherapeutics for hepatocellular carcinoma

References

• Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019 April 10;380(15):1450–1462. .
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. ‘EASL clinical practice guidelines: management of hepatocellular carcinoma’. J Hepatol. 2018;69(1):182–236. July.
   PubMed Web of Science ®Google Scholar
• Keating GM. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 2017;12(2):243–253.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 July 24;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 January;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across child-Pugh subgroups: the GIDEON study. J Hepatol . 2016;65(6):1140–1147. December. .
   PubMed Web of Science ®Google Scholar
• Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54(6):2055–2063. Baltimore, Md.. December. .
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Bhoori S, Germini A, et al. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient’s outcome in advanced hepatocellular carcinoma. Liver Int. 2016;36(7):1033–1042.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Bucci L, Garuti F, et al. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology. 2018;67(5):1784–1796. May.
   PubMed Web of Science ®Google Scholar
• Tovoli F, Casadei-Gardini A, Benevento F, et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019 December 1;71(6):1175–1183.
   PubMed Web of Science ®Google Scholar
• Díaz‐González A, Sanduzzi-Zamparelli M, Sapena V, et al. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2019;49(5):482–491.
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul J-L, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III Trial. J Hepatol. 2012 October 1;57(4):821–829.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia–pacific trial. Eur J Cancer. 2012;48(10):1452–1465. July.
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng A-L, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67(5):999–1008. November.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Peña CEA, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 April 15;18(8):2290–2300.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012 May 1;56(5):1080–1088.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. May J Cancer Res Clin Oncol. 2018;1445:901–908.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 October 1;16(13):1344–1354.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64(5):1090–1098. May.
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):2. August.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107–120. Baltimore, Md.
   PubMed Web of Science ®Google Scholar
• Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019 December 1;71(6):1164–1174.
   PubMed Web of Science ®Google Scholar
• Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019;70(4):684–691. April.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. August.
   PubMed Web of Science ®Google Scholar
• Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017 December 1;18(12):1624–1636.
   PubMed Web of Science ®Google Scholar
• Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018 July 1;36(19):1913–1921.
   PubMed Web of Science ®Google Scholar
• Yoon SM, Ryoo B-Y, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion. JAMA Oncol. 2018;4(5):661–669. May.
   PubMed Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:1–13. 2014.
   PubMedGoogle Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial’. Lancet. 2018 March 24;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2014 November 17;6(1):89–94.
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Ebert M, Lorenzen S, et al. ASCO- und ESMO-update 2017 – neuigkeiten vom 53. meeting der American society of clinical oncology/ASCO 2017 und European society for medical oncology/ESMO-congress 2017. Z Gastroenterol. 2018;56(4):384–397. April.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Cintoni M, Raoul P, et al. Minimal impact of lenvatinib (Lenvima®) on muscle mass in advanced hepatocellular carcinoma and implications for treatment duration. two cases from the REFLECT study. Eur Rev Med Pharmacol Sci. November 2019. European review for medical and pharmacological sciences. DOI: 10.26355/eurrev_201911_19583
   Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. March.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 October 1;64(19):7099–7109.
   PubMed Web of Science ®Google Scholar
• Liu YC, Wu RH, Wang WS. Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via NF-ΚB inactivation in SK-Hep1 cells. July Oncol Lett. 2017;141:461–467.
   PubMed Web of Science ®Google Scholar
• Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013 July 1;12(7):1322–1331.
   PubMed Web of Science ®Google Scholar
• Frenette CT. The role of regorafenib in hepatocellular carcinoma. Gastroenterol Hepatol. 2017;13(2): 122–124. February.
   Google Scholar
• Center for Drug Evaluation and Research, ‘Regorafenib’, FDA, 2 September 2019, [cited 2020 Dec 10]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/regorafenib.
   Google Scholar
• EMA Approval of regorafenib for the treatment of HCC progressing on sorafenib. EMA/CHMP/386334/2017). [ cited 2020 Dec 8] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002573/WC500229885.pdf
   Google Scholar
• Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2016 September 21;3: 31–36.
   PubMed Web of Science ®Google Scholar
• Cerrito L, Ponziani FR, Garcovich M, et al. Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opin Pharmacother. 2018 November 22;19(17):1941–1948.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 January 7;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol. 2018;69(2):353–358. August.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Chang SW, Kim JH, et al. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. Invest New Drugs. 2020 August 4;39(1):260–268. .
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Ooka Y, Itokawa N, et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in japan. Invest New Drugs. 2020 February 1;38(1):172–180.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, MA AEA, Sacco R. Efficacy of regorafenib in hepatocellular carcinoma patients: a systematic review and meta-analysis. Cancers (Basel). 2019 December 20;12(1):36. .
   PubMed Web of Science ®Google Scholar
• Yoo C, Park J-W, Kim YJ, et al. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Invest New Drugs. 2019;37(3):567–572.
   PubMed Web of Science ®Google Scholar
• Iavarone M, Invernizzi F, Czauderna C, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. Am J Transplant. 2019;19(11):3176–3184.
   PubMed Web of Science ®Google Scholar
• Bruix J, Merle P, Granito A, et al. Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib. J Clin Oncol. 2018 February 1;36(4_suppl):412.
   Web of Science ®Google Scholar
• Rimassa L, Wörns MA. Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma. August Liver Int. 2020;40(8):1800–1811.
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Ishigami M, Ito T, et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res. 2019;49(9):1054–1065.
   PubMed Web of Science ®Google Scholar
• Huang A, Yang X-R, Chung W-Y, et al. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020 August 11;5(1). DOI: 10.1038/s41392-020-00264-x
   Web of Science ®Google Scholar
• Uchikawa S, Kawaoka T, Aikata H, et al. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res. 2018;48(10):814–820.
   PubMed Web of Science ®Google Scholar
• Yukimoto A, Hirooka M, Hiraoka A, et al. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma’. Jpn J Clin Oncol. 2019 January 1;49(1):42–47.
   PubMed Web of Science ®Google Scholar
• Von Felden J. New systemic agents for hepatocellular carcinoma: an update 2020. May Curr Opin Gastroenterol. 2020;363:177–183.
   PubMed Web of Science ®Google Scholar
• Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun. 2006 June 23;345(1):438–445.
   PubMed Web of Science ®Google Scholar
• Tugues S, et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011 Apr;32(2):88-111. doi: 10.1016/j.mam.2011.04.004. Epub 2011 May 6.
   Google Scholar
• Amini A, Masoumi Moghaddam S, L. Morris D, et al. The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets. 2012;12(1):23–43. January.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292–301. May.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 July 1;16(7):859–870.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.’. J Clin Oncol. 2018 May 20;36(15_suppl):4003.
   Web of Science ®Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 February 1;20(2):282–296.
   PubMed Web of Science ®Google Scholar
• Kudo M, Okusaka T, Motomura K, et al. Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following First-Line Sorafenib: pooled Efficacy and Safety in Japanese Patients across Two Global Randomized Phase III Studies (REACH-2 and REACH). J Clin Oncol. 2019 January 29;37(4_suppl):320.
   Web of Science ®Google Scholar
• Kuzuya T, ISHIGAMI M, ITO T, et al. Initial experience of ramucirumab treatment after lenvatinib failure for patients with advanced hepatocellular carcinoma’. Anticancer Res. 2020;40(4):2089–2093. April.
   PubMed Web of Science ®Google Scholar
• Kudo M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma. Liver Cancer. 2018;7(2):123–133. May.
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):871–873. 01.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res off J Am Assoc Cancer Res. 2014 June 1;20(11):2959–2970.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018 July 5;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528–534. 01.
   PubMed Web of Science ®Google Scholar
• Merle P, Rimassa L, Ryoo B, et al. Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)’. Ann Oncol. 2018;29:v104.
   Web of Science ®Google Scholar
• Kelley RK, Ryoo B-Y, Merle P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020;5(4):e000714. August.
   PubMed Web of Science ®Google Scholar
• Vesque AD, Decraecker M, Blanc JF. Profile of cabozantinib for the treatment of hepatocellular carcinoma: patient selection and special considerations’. J Hepatocell Carcinoma. 2020;7:91–99.
   PubMed Web of Science ®Google Scholar
• Blanc JF, Meyer T, Cheng A-L, et al. Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2018;29:viii237. October.
   Web of Science ®Google Scholar
• Yau T, Cheng A-L, Meyer T, et al. Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol. 2018;29:viii237–38.
   Web of Science ®Google Scholar
• Rimassa L, Cicin I, Blanc J-F, et al. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (Pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2018 May 20;36(15_suppl):4090.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Mollon P, Meyer T, et al. Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (AHCC) in the CELESTIAL Trial. J Clin Oncol. 2019 January 29;37(4_suppl):207.
   Web of Science ®Google Scholar
• Freemantle N, Abou-Alfa GK, Cheng A-L, et al. Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (AHCC) after sorafenib: qtwist analysis from the CELESTIAL study. Ann Oncol. 2019;30:v290.
   PubMed Web of Science ®Google Scholar
• Soto-Perez-de-Celis E, Aguiar PN, Cordón ML, et al. Cost-effectiveness of cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. J Natl Compr Canc Netw. 2019;17(6):669–675. 01.
   PubMed Web of Science ®Google Scholar
• Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—a cost-effectiveness analysis. PLoS One. 2018 November 8;13(11):e0207132.
   PubMed Web of Science ®Google Scholar
• Locy H, De Mey S, De Mey W, et al. Immunomodulation of the tumor microenvironment: turn foe into friend. Front Immunol. 2018;9:2909.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 March 4;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Pedersen AW, Kopp KL, Andersen MH, et al. Immunoregulatory antigens-novel targets for cancer immunotherapy. Chin Clin Oncol. 2018;7(2):19. April.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJA. Guide to cancer immunotherapy: from t cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668.
   PubMed Web of Science ®Google Scholar
• Robert CA. Decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020 July 30;11(1):3801.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Nicoletti A, Gasbarrini A, et al. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184.
   Web of Science ®Google Scholar
• Ponziani FR, Zocco MA, Cerrito L, et al. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018;12(7):641–656. July.
   PubMed Web of Science ®Google Scholar
• Nicoletti A, Ponziani FR, Biolato M, et al. Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019 September 7;25(33):4814–4834.
   PubMed Web of Science ®Google Scholar
• Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. December J Hepatol. 2014;616:1385–1396.
   PubMed Web of Science ®Google Scholar
• Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol. 2014;60(6):1310–1324. June.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene. 2020;39(18):3620–3637.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med . 2020;382(20):1894–1905. 14.
   PubMed Web of Science ®Google Scholar
• Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17(8):1063–1072.
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008 June 20;26(18):2992–2998.
   PubMed Web of Science ®Google Scholar
• Thomas MB, Garrett-Mayer E, Anis M, et al. A randomized phase II open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma. Oncology. 2018;94(6):329–339.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Baron AD, Malfertheiner P, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by child-Pugh score. JAMA Oncol. 2017 February 1;3(2):235–243.
   PubMed Web of Science ®Google Scholar
• Kudo M. Combination cancer immunotherapy with molecular targeted agents/anti-CTLA-4 antibody for hepatocellular carcinoma. February Liver Cancer. 2019;81:1–11.
   PubMed Web of Science ®Google Scholar
• Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320–341.
   PubMed Web of Science ®Google Scholar
• AstraZeneca A Randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma’, Clinical trial registration ( clinicaltrials.gov, 25 August 2020), [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT03298451.
   Google Scholar
• Squibb B-M. A randomized, multi-center, phase 3 study of nivolumab in combination with ipilimumab compared to sorafenib or lenvatinib as first-line treatment in participants with advanced hepatocellular carcinoma. Clinical trial registration ( clinicaltrials.gov, 18 November 2020), [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT04039607.
   Google Scholar
• A study of nivolumab in participants with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation - full text view - clinicaltrials.gov. 458, [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT03383458.
   Google Scholar
• Sharp M, Corp D. A phase 3 double-blinded, two-arm study to evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma and complete radiological response after surgical resection or local ablation (KEYNOTE-937). Clinical trial registration ( clinicaltrials.gov, 1 December 2020), [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT03867084.
   Google Scholar
• AstraZeneca A Phase III, randomized, double-blind, placebo-controlled, multi center study of durvalumab monotherapy or in combination with bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation. Clinical trial registration ( clinicaltrials.gov, 20 November 2020), [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT03847428.
   Google Scholar
• Roche H-L. A phase III, multicenter, randomized, open-label study of atezolizumab (Anti-PD-L1 Antibody) Plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation. Clinical trial registration ( clinicaltrials.gov, 18 November 2020), [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT04102098.
   Google Scholar
• Tovoli F, Casadei-Gardini A, Benevento F, et al. Immunotherapy for hepatocellular carcinoma: a review of potential new drugs based on ongoing clinical studies as of 2019. Dig Liver Dis. 2019;51(8):1067–1073.
   PubMedGoogle Scholar
• Safety and efficacy of lenvatinib (E7080/MK-7902) with pembrolizumab (MK-3475) in combination with transarterial chemoembolization (TACE) in participants with incurable/non-metastatic hepatocellular carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) - full text view - clinicaltrials.gov, accessed 5 December 2020, [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT04246177.
   Google Scholar
• Zhong JH Drug-eluting bead transarterial chemoembolization plus lenvatinib or sorafenib or PD-1 inhibitor for unresectable hepatocellular carcinoma: a multicentric prospective study. Clinical trial registration ( clinicaltrials.gov, 20 January 2020), [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT04229355.
   Google Scholar
• Global A Study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma (EMERALD-1) full text view - clinicaltrials.gov’, [cited 2020 Dec 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT03778957.
   Google Scholar
• Roskell N, Gregory J, Wisniewski T, et al. ‘PCN17 - indirect treatment comparisons of nivolumab versus regorafenib, cabozantinib and best supportive care after treatment with sorafenib for hepatocellular carcinoma. Value Health. 2018;21:S17–18. October.
   Web of Science ®Google Scholar
• Bakouny Z, Assi T, El Rassy E, et al. Second-line treatments of advanced hepatocellular carcinoma: systematic review and network meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2019;53(4):251–261.
   PubMed Web of Science ®Google Scholar
• D’Angelo A, Sobhani N, Bagby S, et al. Cabozantinib as a second-line treatment option in hepatocellular carcinoma’. Expert Rev Clin Pharmacol. 2020;13(6):623–629. June.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Mollon P, Blanc J-F, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther. 2020;6(37):2678–2695.
   Google Scholar
• Wang D, Yang X, Lin J, et al. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therap Adv Gastroenterol. 2020;13:1756284820932483.
   Web of Science ®Google Scholar
• Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107–120. Epub 2018 Jul 10. PMID: 29665135
   PubMed Web of Science ®Google Scholar
• Giannini EG, Aglitti A, Borzio M, et al. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.CA cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers (Basel). 2019Oct30;11(11)1689. Basel. PMID: 31671581; PMCID: PMC6896125.
   Web of Science ®Google Scholar
• Ponziani FR, Nicoletti A, Gasbarrini A, et al. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;10(11):1758835919848184. PMID: 31205505; PMCID: PMC6535703
   Google Scholar
• Piñero F, Silva M, Iavarone M. Sequencing of Systemic treatment for hepatocellular carcinoma: second line competitors. World J Gastroenterol. 2020 April 28;26(16):1888–1900.
   PubMed Web of Science ®Google Scholar
• Von Felden J, Garcia-Lezana T, Schulze K, et al. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020;69(11):2025–2034.
   PubMed Web of Science ®Google Scholar